Published in J Clin Oncol on October 01, 1995
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res (2006) 1.69
Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res (2014) 1.13
Clinical trials in the era of personalized oncology. CA Cancer J Clin (2011) 1.13
Taxanes for the treatment of metastatic breast cancer. Breast Cancer (Auckl) (2012) 1.02
A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics (1996) 1.02
Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist (2011) 0.98
Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics (2012) 0.94
Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat (2013) 0.90
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy). Invest New Drugs (2008) 0.89
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Br J Cancer (2004) 0.88
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs (2007) 0.87
Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. Br J Cancer (2001) 0.86
Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus (2014) 0.84
Weekly docetaxel in the treatment of metastatic breast cancer. Ther Clin Risk Manag (2008) 0.78
Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study Group. Invest New Drugs (1998) 0.78
Current approaches to the management of Her2-negative metastatic breast cancer. Breast Cancer Res (2012) 0.77
Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients. BMC Cancer (2013) 0.77
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer. BMC Cancer (2006) 0.77
Paclitaxel impairs adipose stem cell proliferation and differentiation. J Surg Res (2015) 0.77
Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment. Am J Cancer Res (2016) 0.76
Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer. J Oncol (2012) 0.75
Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer. Br J Cancer (2001) 0.75
A close look at therapeutic touch. JAMA (1998) 9.68
The epic project: developing national evidence-based guidelines for preventing healthcare associated infections. Phase I: Guidelines for preventing hospital-acquired infections. Department of Health (England). J Hosp Infect (2001) 4.95
With nurse practitioners, who needs house officers? BMJ (1995) 4.16
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene (2006) 3.48
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.06
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
BRCA-associated breast cancer in young women. J Clin Oncol (1998) 2.78
Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol (1999) 2.61
Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet (1996) 2.40
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol (1999) 2.19
Comparison of time spent writing orders on paper with computerized physician order entry. Stud Health Technol Inform (2001) 2.18
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol (1999) 1.84
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol (2009) 1.83
Proof of the pudding. CASPE's patient satisfaction system. Health Serv J (1989) 1.75
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst (1999) 1.73
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol (1998) 1.68
Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy. Neurology (2005) 1.63
A randomised comparison of two intranasal dexmedetomidine doses for premedication in children. Anaesthesia (2012) 1.56
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res (2000) 1.48
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat (2001) 1.46
Smoking cessation and severity of disease: the Coronary Artery Smoking Intervention Study. Health Psychol (1992) 1.46
Increased DMT1 but not IREG1 or HFE mRNA following iron depletion therapy in hereditary haemochromatosis. Gut (2004) 1.45
Clinical expression of haemochromatosis in Irish C282Y homozygotes identified through family screening. Eur J Gastroenterol Hepatol (2004) 1.44
Multiple pulmonary aspergillomas. JBR-BTR (2009) 1.39
Development of clinical audit. Br J Hosp Med (1989) 1.39
The impact of the sequence of radiation and chemotherapy on local control after breast-conserving surgery. Cancer J Sci Am (2006) 1.38
Intervention study to evaluate pilot health promotion payment aimed at increasing general practitioners' antismoking advice to smokers. BMJ (2001) 1.37
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol (2006) 1.37
Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat (2011) 1.33
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol (1985) 1.31
A randomised controlled trial of nasal continuous positive airway pressure on insulin sensitivity in obstructive sleep apnoea. Eur Respir J (2009) 1.28
Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine (1994) 1.28
Multi-method psycho-educational intervention for preschool children with disruptive behavior: preliminary results at post-treatment. J Child Psychol Psychiatry (2000) 1.27
HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets (2009) 1.25
Commercial hair analysis. Science or scam? JAMA (1985) 1.24
Underdiagnosis of hereditary haemochromatosis: lack of presentation or penetration? Gut (2002) 1.23
Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol (2011) 1.23
The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut (2005) 1.22
Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population. JAMA (1997) 1.21
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res (2007) 1.20
Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol (2000) 1.19
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol (2006) 1.14
Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol (2010) 1.13
Evaluation of PCR for diagnosis of melioidosis. J Clin Microbiol (1998) 1.12
Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer (2005) 1.12
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat (2004) 1.12
Intrusive thoughts and psychological distress among breast cancer survivors: global meaning as a possible protective factor. Behav Med (2000) 1.11
Elevated plasma adiponectin levels in patients with chronic obstructive pulmonary disease. Int J Tuberc Lung Dis (2010) 1.11
Social support, intrusive thoughts, and quality of life in breast cancer survivors. J Behav Med (2001) 1.09
BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res (1998) 1.09
GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res (1995) 1.09
Smoking cessation treatment in primary care: prospective cohort study. Tob Control (2005) 1.08
Extending prescribing: issues and opportunities. J R Coll Physicians Lond (2000) 1.06
The practice of polypharmacy involving herbal and prescription medicines in the treatment of diabetes mellitus, hypertension and gastrointestinal disorders in Jamaica. West Indian Med J (2004) 1.06
The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist (2011) 1.05
BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications. Crit Rev Oncol Hematol (2012) 1.05
Native cellular fluorescence of neoplastic upper aerodigestive mucosa. Arch Otolaryngol Head Neck Surg (1995) 1.05
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol (2012) 1.05
ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol (2008) 1.04
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer (2011) 1.04
Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol (1993) 1.02
Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res (2001) 1.01
MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Res (2007) 1.01
Attention-deficit hyperactivity disorder and the stress response. Biol Psychiatry (1998) 1.00
GFP-centrin as a marker for centriole dynamics in the human breast cancer cell line MCF-7. Ital J Anat Embryol (2001) 1.00
Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test (1997) 1.00
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol (1995) 1.00
Changes in HIV testing rates among patients with tuberculosis in a large multiethnic city in the UK. Int J STD AIDS (2011) 0.98
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs (2012) 0.98
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol (1999) 0.97
Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol (2012) 0.97
Genetic hemochromatosis, a Celtic disease: is it now time for population screening? Genet Test (2001) 0.96
The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol (2011) 0.96
ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann Oncol (2012) 0.95
Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst (1995) 0.95
5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study. J Clin Oncol (1999) 0.94
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol (2011) 0.94
Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer. Br J Cancer (2006) 0.94
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. Invest New Drugs (2009) 0.93
Penile ulcer in heroin abuse: a case report. Cutis (1982) 0.93
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol (1996) 0.92
The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol (2012) 0.92
Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res (1996) 0.91